Insilico expands Tenacia CNS pact in deal worth up to $94.75M
CURRENT FULL VERSION: Insilico Medicine is expanding its AI-driven CNS alliance with Tenacia Biotechnology in a deal worth up to $94.75 million, adding a second neurological disease program to a partnership that began a year ago. In the March 26, 2026 announcement, the companies said the new phase will use Insilico’s generative drug discovery platform, Pharma.AI, alongside Tenacia’s neuroscience expertise and proprietary data to develop an additional candidate with defined properties and advance it to the preclinical candidate stage. Insilico said it is eligible for near-term and milestone payments under the agreement. (prnewswire.com)
The expansion follows the initial March 2025 collaboration between the companies, which focused on small-molecule inhibitors designed for strong blood-brain barrier permeability, a key challenge in CNS drug development. According to the companies, that first program has progressed well enough to justify broadening the relationship. Tenacia, founded in 2022 and backed by Bain Capital Life Sciences, has positioned itself around underserved neurological disorders in China, while Insilico has been using partnerships to validate and monetize its AI platform across multiple therapeutic areas. (prnewswire.com)
The timing also fits Insilico’s broader business push. The company listed on the Hong Kong Stock Exchange on December 30, 2025 under stock code 3696, and has since continued to stack partnership announcements around AI-enabled discovery. In January 2026, Insilico said a separate CNS program, ISM8969, received FDA clearance to begin clinical testing in Parkinson’s disease under a co-development arrangement with Hygtia Therapeutics. Days after the Tenacia expansion, Eli Lilly also expanded its relationship with Insilico in a multibillion-dollar AI drug discovery agreement. Under that Lilly collaboration, Insilico is set to receive $115 million upfront and could earn up to about $2.75 billion in development, regulatory, and commercial milestones, plus tiered royalties on future sales. Lilly gained exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for selected indications, and the companies also agreed to work together on multiple R&D programs against Lilly-selected targets using Pharma.AI. Those terms help explain why large pharma and biotech partners are still willing to pay for access not just to AI software, but to preclinical assets and target-focused discovery capabilities. (prnewswire.com; pharmashots.com)
The key detail in the Tenacia deal is not just the headline value, but the structure and scope. This is an expansion, not a brand-new alliance, and it centers on creating a second molecule against the same broad CNS challenge with distinct properties. Insilico’s founder and CEO Alex Zhavoronkov framed that as evidence that generative AI can quickly produce multiple differentiated candidates around a target profile, potentially offering partners more than one shot on goal before entering costly late-stage development. That matters in neuroscience, where attrition rates remain high and translational gaps between preclinical promise and clinical performance are especially pronounced. (prnewswire.com)
Public expert commentary on this specific deal appears limited so far, but the industry context is clear: AI drug discovery companies are increasingly being judged less on technology demos and more on whether partners come back for additional programs. The recent Lilly expansion is one example of that broader pattern, and its disclosed structure adds another useful signal: major companies are willing to commit meaningful upfront cash, exclusive commercialization rights, and long-tail milestone economics when they see value in AI-enabled preclinical candidates and target-selection workflows. Inference: Tenacia’s decision to add another program after one year likely reflects at least some internal confidence in the first collaboration’s output, even though the companies have not disclosed the target or candidate data behind that decision. (techtarget.com; pharmashots.com)
Why it matters: For veterinary professionals, the direct clinical relevance is limited today, because this is a human biopharma CNS partnership rather than an animal health launch. Still, it’s useful intelligence. Neurology is a difficult category in both human and veterinary medicine, and tools that improve early-stage molecule design, especially around blood-brain barrier penetration, could eventually shape how animal health companies evaluate external innovation. Insilico explicitly says its AI platform reaches into veterinary medicine, so developments like this may be early indicators of how future companion animal CNS candidates are sourced, screened, and partnered. More broadly, the deal shows that AI in drug discovery is continuing to move upstream from software access toward asset creation and milestone economics, a model veterinary R&D teams may increasingly encounter. The Lilly collaboration strengthens that readout because it pairs platform access with exclusive rights to preclinical oral candidates and substantial upfront economics, suggesting the market is rewarding AI companies that can deliver tangible assets rather than just discovery tools. (prnewswire.com; pharmashots.com)
What to watch: The next meaningful milestones will be whether the companies identify the target, disclose preclinical data, or announce nomination of a preclinical candidate. It will also be worth watching whether Tenacia keeps this work China-focused or uses the collaboration to support broader geographic ambitions, and whether Insilico continues translating CNS platform work into additional alliances, including any that touch animal health more directly. Separately, Insilico’s mix of smaller disease-area partnerships and larger multi-program deals like Lilly’s may offer a useful read on how AI drug discovery business models are maturing. (prnewswire.com; pharmashots.com)